Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970398 | 0.85 | CDC7 (0.39) | HTR6PIM1PIM2EGFR | |
| SCHEMBL1048604 | 0.82 | BRD4 (0.43) | USP30HTR6CNR1CNR2BRD4 | |
| SCHEMBL1046987 | 0.81 | HTR6 (0.39) | USP30HTR6BCHECNR1CNR2 | |
| SCHEMBL1051244 | 0.80 | GPR119 (0.41) | HTR6CNR1CNR2BRD4PRMT5 | |
| SCHEMBL1047181 | 0.80 | HTR6 (0.48) | USP30HTR6BCHEBRD4APLNR | |
| SCHEMBL970112 | 0.75 | HTR6 (0.38) | USP30HTR6PIM1 | |
| SCHEMBL30204065 | 0.74 | DGAT2 (0.41) | USP30HTR6BCHEPIM1PIM2 | |
| SCHEMBL25596655 | 0.74 | DGAT2 (0.41) | USP30HTR6BCHEPIM1PIM2 | |
| SCHEMBL958790 | 0.74 | MAPK14 (0.51) | — | |
| SCHEMBL952331 | 0.74 | CYP2C19 (0.44) | HTR6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454262-B1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LAB (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8383624-B2 | Pyrrolopyrazine inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | USP30 2477/4885HTR6 4700/4885BCHE 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.